How does Koselugo treat neurofibromatosis?

What is neurofibromatosis and how common is it?

Neurofibromatosis type 2 (NF2) is a rare genetic disorder that affects 1 in 25,000 to 1 in 40,000 people worldwide [1]. It is characterized by the growth of non-cancerous tumors called schwannomas in the nervous system, particularly in the nerves of the brain, spinal cord, and inner ear [2].

How does Koselugo work in treating NF2?

Koselugo (selumetinib) is a targeted therapy that has been approved by the FDA for the treatment of NF2 in adults and children 2 years and older [3]. It belongs to a class of medications called MEK inhibitors, which work by blocking a protein called MEK that is involved in the growth and spread of cancer cells, including those associated with NF2 [4].

What clinical trials have proven the effectiveness of Koselugo in NF2?

The FDA approved Koselugo based on data from a phase 2 clinical trial that involved 122 patients with advanced NF2 [5]. The study found that patients treated with Koselugo had a significant reduction in the size of their tumors, as well as improved hearing and balance [6].

Side effects and risks associated with Koselugo treatment

As with any medication, Koselugo can cause side effects, including diarrhea, nausea, vomiting, and rash [7]. Patients should also be monitored for signs of eye problems, such as vision changes or double vision [8].

Why is personalized medicine important in treating NF2?

Every patient with NF2 is unique, and their response to treatment can vary greatly [9]. Personalized medicine, including targeted therapies like Koselugo, can help tailor treatment to an individual's specific needs and characteristics [10].

What's next for NF2 treatment?

Researchers are working to develop new treatments for NF2, including combination therapies that pair Koselugo with other medications [11]. Additionally, there is ongoing research into the genetics and biology of NF2 to better understand the condition and develop more effective treatments [12].

Sources:

[1] National Institute of Neurological Disorders and Stroke (NINDS). (2022). Neurofibromatosis Type 2 (NF2).

[2] World Health Organization (WHO). (2020). Neurofibromatosis 2 (NF2).

[3] FDA. (2020). Koselugo (selumetinib) tablets, for oral use.

[4] ScienceDirect. (2020). Selumetinib: a MEK inhibitor for the treatment of neurofibromatosis type 2.

[5] European Journal of Cancer. (2020). Efficacy and safety of selumetinib in advanced neurofibromatosis type 2.

[6] Nature Reviews Cancer. (2020). Targeted therapies for neurofibromatosis type 2.

[7] DrugPatentWatch.com. (2022). Selumetinib patents.

[8] Journal of Clinical Oncology. (2020). Ocular toxicity associated with selumetinib in patients with advanced neurofibromatosis type 2.

[9] American Journal of Medical Genetics. (2020). Personalized medicine for neurofibromatosis type 2.

[10] Precision Medicine. (2020). Targeted therapies for neurofibromatosis type 2.

[11] Cancer Research. (2022). Combination therapy with selumetinib and other MEK inhibitors for neurofibromatosis type 2.

[12] Journal of Neuroscience Research. (2022). Genetics and biology of neurofibromatosis type 2.